Quintet Private Bank Europe S.A. Buys 1,418 Shares of Stryker Co. (NYSE:SYK)

Quintet Private Bank Europe S.A. grew its position in shares of Stryker Co. (NYSE:SYK) by 24.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,230 shares of the medical technology company’s stock after buying an additional 1,418 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Stryker were worth $2,612,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Centennial Bank AR raised its stake in Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the last quarter. Central Pacific Bank Trust Division bought a new stake in shares of Stryker during the 1st quarter valued at about $39,000. HBW Advisory Services LLC bought a new position in shares of Stryker in the 3rd quarter worth approximately $42,000. Grove Bank & Trust increased its holdings in Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after buying an additional 56 shares during the last quarter. Finally, DT Investment Partners LLC boosted its stake in shares of Stryker by 114.3% during the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock worth $49,000 after acquiring an additional 72 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of Stryker stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 190,000 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the completion of the transaction, the director now directly owns 3,316,608 shares in the company, valued at approximately $1,072,790,023.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 200,068 shares of company stock worth $65,151,372. Company insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.1 %

Shares of NYSE SYK traded down $0.43 during mid-day trading on Monday, reaching $366.72. 89,305 shares of the company were exchanged, compared to its average volume of 1,253,533. Stryker Co. has a 1 year low of $266.93 and a 1 year high of $374.63. The firm has a 50-day moving average of $360.18 and a 200 day moving average of $344.36. The stock has a market cap of $139.80 billion, a price-to-earnings ratio of 39.35, a P/E/G ratio of 2.69 and a beta of 0.91. The company has a quick ratio of 0.95, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the business posted $2.46 EPS. Stryker’s revenue was up 11.9% on a year-over-year basis. On average, research analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.87%. The ex-dividend date was Monday, September 30th. Stryker’s payout ratio is 34.30%.

Analyst Ratings Changes

A number of analysts have commented on SYK shares. Canaccord Genuity Group upped their price target on Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Stifel Nicolaus lowered their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Evercore ISI lifted their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. BTIG Research upped their target price on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Truist Financial raised their price objective on Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.